Amiloride and urinary trypsin inhibitor inhibit urothelial cancer invasion. 2003

Natsuo Oka, and Yuushi Okumura, and Hiro-Omi Kanayama, and Hirofumi Izaki, and Masumi Okamoto, and Hiroshi Kido, and Susumu Kagawa
Department of Urology, The University of Tokushima School of Medicine, 3-18-15, Kuramoto-Cho, Tokushima 770-8503, Japan.

OBJECTIVE To determine the contribution of urokinase-type plasminogen activator (uPA) and plasmin in the invasion of highly invasive urothelial cancer cells. METHODS We compared expression levels of mRNA and protease activity of uPA and plasmin formation in primary cultures of the noninvasive transitional cell carcinoma, UCT-1, and in the highly invasive type, UCT-2. By using in vitro cell invasion assay system, we evaluated the effects of amiloride and urinary trypsin inhibitor (UTI), which inhibit uPA and plasmin, respectively, on invasion by both cell lines. RESULTS Expression levels of mRNA, protein, and activities of uPA were significantly higher (p<0.005) and resulted in more plasminogen activation in UCT-2 than in UCT-1. Amiloride and UTI significantly inhibited plasmin formation and the invasion of both cell lines (p<0.001). CONCLUSIONS High expression levels of mRNA, activities of uPA and high plasmin formation significantly potentiated the invasiveness of urothelial cancer cells. Thus, inhibitors of uPA and plasmin, such as amiloride and UTI, respectively, could be useful therapeutic tools with which to treat urothelial cancer.

UI MeSH Term Description Entries
D008297 Male Males
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000584 Amiloride A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705) Amidal,Amiduret Trom,Amiloberag,Amiloride Hydrochloride,Amiloride Hydrochloride, Anhydrous,Kaluril,Midamor,Midoride,Modamide,Anhydrous Amiloride Hydrochloride,Hydrochloride, Amiloride,Hydrochloride, Anhydrous Amiloride,Trom, Amiduret
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D014361 Trypsin Inhibitors Serine proteinase inhibitors which inhibit trypsin. They may be endogenous or exogenous compounds. Trypsin Inhibitor,Inhibitor, Trypsin,Inhibitors, Trypsin

Related Publications

Natsuo Oka, and Yuushi Okumura, and Hiro-Omi Kanayama, and Hirofumi Izaki, and Masumi Okamoto, and Hiroshi Kido, and Susumu Kagawa
October 1989, Hinyokika kiyo. Acta urologica Japonica,
Natsuo Oka, and Yuushi Okumura, and Hiro-Omi Kanayama, and Hirofumi Izaki, and Masumi Okamoto, and Hiroshi Kido, and Susumu Kagawa
March 1994, Clinical & experimental metastasis,
Natsuo Oka, and Yuushi Okumura, and Hiro-Omi Kanayama, and Hirofumi Izaki, and Masumi Okamoto, and Hiroshi Kido, and Susumu Kagawa
April 1985, Rinsho byori. The Japanese journal of clinical pathology,
Natsuo Oka, and Yuushi Okumura, and Hiro-Omi Kanayama, and Hirofumi Izaki, and Masumi Okamoto, and Hiroshi Kido, and Susumu Kagawa
December 1999, Nihon rinsho. Japanese journal of clinical medicine,
Natsuo Oka, and Yuushi Okumura, and Hiro-Omi Kanayama, and Hirofumi Izaki, and Masumi Okamoto, and Hiroshi Kido, and Susumu Kagawa
July 2010, Nihon rinsho. Japanese journal of clinical medicine,
Natsuo Oka, and Yuushi Okumura, and Hiro-Omi Kanayama, and Hirofumi Izaki, and Masumi Okamoto, and Hiroshi Kido, and Susumu Kagawa
August 2005, Nihon rinsho. Japanese journal of clinical medicine,
Natsuo Oka, and Yuushi Okumura, and Hiro-Omi Kanayama, and Hirofumi Izaki, and Masumi Okamoto, and Hiroshi Kido, and Susumu Kagawa
September 1983, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
Natsuo Oka, and Yuushi Okumura, and Hiro-Omi Kanayama, and Hirofumi Izaki, and Masumi Okamoto, and Hiroshi Kido, and Susumu Kagawa
May 1994, International journal of cancer,
Natsuo Oka, and Yuushi Okumura, and Hiro-Omi Kanayama, and Hirofumi Izaki, and Masumi Okamoto, and Hiroshi Kido, and Susumu Kagawa
January 1969, Enzymologia biologica et clinica,
Natsuo Oka, and Yuushi Okumura, and Hiro-Omi Kanayama, and Hirofumi Izaki, and Masumi Okamoto, and Hiroshi Kido, and Susumu Kagawa
September 1983, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
Copied contents to your clipboard!